Curasight opens phase 1 trial for brain cancer treatment

Curasight A/S (market value ~$45.46M; share price $0.99) announced EMA approval and the opening of its Phase 1 trial for uTREAT in glioblastoma, with first patient dosing expected before end-2025. The stock has rallied recently (14.7% over the past week; +50.23% over six months) as the company advances its theranostic platform (uTRACE/uTREAT) targeting uPAR, which is expressed in ~94% of glioblastoma tumors; the addressable US/EU incidence cited is ~30,000 patients annually. Financials show a diluted LTM EPS of -$0.20, Price/Book of 9.69, a current ratio of 2.65 and more cash than debt; earnings are scheduled for Nov. 27. The development is a meaningful clinical milestone likely to drive investor interest in this small-cap biotech, but commercial and profitability risks remain given early-stage status.

Analysis

Market structure: Curasight (CPH:CURAS) is a direct beneficiary of renewed investor appetite for theranostics; a Phase‑1 trial and EMA approval materially de‑risks regulatory entry but not commercialisation — 30k annual glioblastoma patients (US+EU) imply a theoretical peak TAM in hundreds of millions of USD, yet real revenue depends on later phase success and reimbursement. Incumbent external beam radiation providers and generic radiotherapy consumable suppliers are potential long‑run losers if uTREAT shows durable tumor control and reduced side‑effects, but pricing power will be weak until Phase‑2/3 data; expect gradual share shifts over multiple years, not immediate displacement.

Risk assessment: Tail risks are binary and large — trial safety failure, operational inability to manufacture short‑lived isotopes, or equity dilution (market cap ~$45.5m, EPS -$0.20) can erase >80% of value. Timeline buckets: immediate (days–weeks) = sentiment swings and liquidity volatility; short (3–12 months) = patient dosing and early safety signals (first dosing target by end‑2025); long (12+ months) = pivotal trials, partner/M&A or commercialization; hidden dependency = reliable radioisotope supply chain and payer acceptance.

Trade implications: Size positions small and stage‑based: micro‑cap biotech downside is asymmetric; prefer 1–2% portfolio exposure to CURAS with strict stop and financing triggers. Use options (if liquid) to lever upside with defined loss: 12–18 month calls 20–30% OTM sized ≤0.5% AUM, or buy equity and pair with 25% OTM protective puts; hedge sector beta by shorting 0.5–0.75% of a broad biotech ETF (IBB/XBI).

Contrarian angles: The market celebrates regulatory green‑lights but underestimates that Phase‑1 is safety/PK only — current PB 9.7 and +50% 6‑month move suggest efficacy expectations are priced in. Historical parallel: numerous radiopharma microcaps spike on Phase‑1 then collapse on dosing delays or dilution; if CURAS fails to dose by 90 days past its target or raises equity that halves pre‑raise share price, the current rally is likely overextended.

Key Decisions for Investors

• Establish a tactical long of 1–1.5% portfolio in Curasight (CPH:CURAS): buy 50% now and 50% on confirmed first‑patient dosing announcement (targeted by end‑2025). Set a hard stop at −30% and a take‑profit plan to exit or re‑hedge at +100% or on positive safety signal.
• If liquid, purchase 12–18 month calls on CURAS ~20–30% OTM sized no more than 0.5% AUM to capture asymmetric upside; if options unavailable, buy stock and buy a 25% OTM protective put (6–12 month) to cap loss.
• Hedge sector beta by shorting 0.5–0.75% AUM of IBB or XBI (equal dollar to the long) to neutralize macro biotech moves; if choosing individual shorts, target microcaps with cash runway <12 months and recent dilution risk.
• Reallocate 2% away from general speculative small‑cap biotech exposure into higher conviction tech names with secular AI tailwinds: add 1% SMCI and 1% APP (reduce overall portfolio idiosyncratic biotech risk).
• Trigger‑based risk rules: if CURAS fails to dose within 90 days of its guidance (end‑2025) or announces a financing that increases shares outstanding >20%, reduce position to 0.25% or exit entirely.